NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said last week that the Paris Tribunal de Grande Instance has dismissed a lawsuit filed against it by Genoway in January.

The third chamber of the Tribunal de Grande Instance returned a verdict stating, among other things, that a contract between Cellectis and Genoway was terminated on December 30, 2008; that the under-license products detained by Genoway must be destroyed; and that an audit of Genoway's accounts is to be resumed in order for Genoway to pay sums owed to Cellectis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.